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Introduction: Previous studies of interstitial lung disease (ILD) suggest that prognosis and ther-
apeutic response are influenced by the presence of underlying collagen vascular disease (CVD).
Yet, what proportion of patients presenting with ILD have CVD is largely unknown. We sought
to determine the frequency of a new CVD diagnosis in an ILD referral population.
Materials/patients and methods: We retrospectively studied 114 consecutive patients evalu-
ated at the Johns Hopkins Interstitial Lung Disease Clinic for the development of CVD.
Results: In this retrospective cohort, nearly one-third of the 114 patients with confirmed ILD
satisfied published criteria for a CVD diagnosis. Seventeen (15%) patients were diagnosed with
a new CVD as a direct consequence of their ILD evaluation. Patients with new CVD diagnosis
were younger than those without new CVD diagnosis: 51.4 years (95% CI 45e58 years) and
60 years (95% CI 57e63), respectively (pZ 0.01). Moreover, an ANA  1:640 (pZ 0.03) and
elevated levels of creatine phosphokinase (CPK) or aldolase (p < 0.001) were associated with
a new CVD diagnosis.
Conclusions: Unrecognized collagen vascular disease may be more common than previously
appreciated among patients referred with ILD. High titer ANA and an elevated CPK or aldolase
are associated with a CVD diagnosis in this referral population.
ª 2009 Elsevier Ltd. All rights reserved.0 955 4176; fax: þ1 410 955 0036.
(S.K. Danoff).
9 Elsevier Ltd. All rights reserved.
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Interstitial lung disease (ILD) may occur in the context of
several collagen vascular diseases (CVDs), including
systemic sclerosis, Sjogren’s syndrome, systemic lupus
erythematosus, rheumatoid arthritis, polymyositis and
dermatomyositis.1 When present, ILD often results in
substantial morbidity and mortality.2 The association of ILD
with an underlying CVD varies widely, based both on the
method used to ascertain ILD (chest radiograph, computed
tomography (CT), pulmonary function testing (PFT) or lung
biopsy) and on the specific CVD. Prevalence estimates of
ILD in patients with an established CVD are largely based on
patients presenting with non-respiratory symptoms of the
respective CVD (e.g. arthritis, weakness, rash, etc.) who
are subsequently evaluated to assess for the presence of
pulmonary disease.3e6 In contrast, the existence of a new
CVD diagnosis in those first presenting to a pulmonologist
with symptoms of ILD, such as cough and dyspnea, remains
largely unknown.
In the early 1970s, autoantibodies were first described in
those with idiopathic pulmonary fibrosis (IPF)7; positive
anti-nuclear antibodies (ANA) were demonstrated in nearly
50% of these patients.7 However, the significance of the
positive ANAs in this setting was unclear as many were of
low titer. Notably, a recent publication hypothesized idio-
pathic non-specific interstitial pneumonitis (NSIP) to be an
autoimmune disorder: the pulmonary manifestation of an
undifferentiated connective tissue disease (UCTD).8
Further, ILD can clearly be the presenting symptom of
several CVDs.9 However, the ability to identify previously
unrecognized and undiagnosed CVD in patients presenting
with ILD has not been systematically evaluated.
The ascertainment of CVD in association with ILD (CVD-
ILD) in contrast to IPF alone is relevant both for prognostic
and therapeutic purposes. Of note, NSIP, the lung histopa-
thology most commonly associated with CVD-ILD,10,11
confers a considerably better prognosis than usual inter-
stitial pneumonitis (UIP), the histopathology associated
with IPF.12 Moreover, appreciation for the limited efficacy
and known toxicities associated with immunosuppressive
therapy for IPF is a relevant consideration in therapeutic
recommendations.13 Thus, it is critically important to
differentiate CVD-ILD patients from those with IPF alone,
inasmuch as the CVD-ILD population would be expected to
experience a more favorable risk-benefit ratio from
treatment.
We therefore sought to determine the frequency of
previously undiagnosed CVD in a cohort of patients pre-
senting to an ILD clinic. Further, we examined the associ-
ation of several common and frequently used laboratory
tests with the diagnosis of a new CVD.
Materials/patients and methods
Study subjects
This was a retrospective study of consecutive patients
referred to the Johns Hopkins Interstitial Lung Disease Clinic
and was approved by the Institutional Review Board. Medical
records of all patients evaluated at the ILD Clinic from June2000 to July 2006 were reviewed. Patients with prior diag-
noses of sarcoidosis or systemic sclerosis were evaluated in
separate subspecialty clinics. A diagnosis of ILD was made
based on criteria including consistent clinical features and
pulmonary function testing, radiographic evidence of inter-
stitial disease, and/or lung histopathology consistent with
this diagnosis.14 All patients referred to our center with ILD
had abnormal high resolution computed tomography scans of
their lungs, scans which were re-reviewed at our center to
confirm the presence of ILD. One hundred-sixty patients
satisfied the criteria for ILD, the majority of whom were
referred for cough or dyspnea. Among this group, 121 (76%)
had at least one autoantibody assayed during their clinical
evaluation. Seven of these patients were excluded from
analysis when their pulmonary disorder was attributed to
medication toxicity (rituximab (nZ 1), amiodarone
(nZ 2)), to asbestos fiber exposure (nZ 1), or attributed to
sarcoidosis (nZ 3). The remaining 114 patients had both
radiographically or histologically confirmed ILD and at least
one autoantibody (antinuclear antibody, anti-Ro, anti-La,
anti-Scl 70 antibody, rheumatoid factor, or myositis-specific
antibody) (Jo-1, anti-PL-7, anti-SRP, anti-Mi-2, anti-EJ, anti-
OJ), ormyositis-associated antibody (anti-Ku) assayedduring
their work-up and form the basis of this analysis.
Study design and methods
Demographic features were uniformly recorded, including
age at presentation to the ILD clinic, first ILD-related
symptom, and presence of muscle weakness on exam.
Laboratory data included the above autoantibodies, as well
as inflammatory markers (erythrocyte sedimentation rate
(ESR) and C-reactive protein (CRP)) obtained within one
month of presentation to the ILD clinic. In addition, available
levels of aspartate aminotransferase (AST), alanine amino-
transferase (ALT), creatine phosphokinase (CPK) and
aldolase closest to presentation were recorded. Results of
lung biopsies, muscle biopsies, and electromyogram (EMG/
NCS) were recorded. Lung biopsies were performed during
routine clinical evaluation in accordance with ATS /ERS
guidelines for the evaluation of idiopathic interstitial pneu-
monias.14 All available lung biopsies were reviewed by a lung
pathologist at Johns Hopkins with expertise in ILD. Disease
duration was defined as the period of time from the first ILD-
related symptom to initial evaluation at the ILD clinic.
The American College of Rheumatology (ACR) criteria for
rheumatoid arthritis (RA), systemic sclerosis (SSc), systemic
lupus erythematosus (SLE), Wegener’s granulomatosis
(WG), primary Sjo¨gren’s syndrome (PSS), and Bohan and
Peter’s criteria for polymyositis (PM) and dermatomyositis
(DM) were used to establish a diagnosis of a CVD.15e20 After
evaluation by a rheumatologist, patients with two or more
signs and symptoms of a CVD (e.g. polyarthralgias/arthritis,
sicca symptoms, Raynaud’s phenomenon) and a positive
ANA without fulfilling criteria for a well defined CVD were
considered to have a UCTD.21e23 In addition, an established
CVD was defined as an existing diagnosis of CVD prior to
presentation to the ILD Clinic. A new diagnosis of CVD was
defined as a diagnosis which satisfied published criteria,
and was established only after and as a result of evaluation
at the ILD Clinic.
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Descriptive statistics including proportions, means and stan-
dard deviations were computed. The ShapiroeWilk test was
used to assess normality of the data. Univariate comparisons
ofpatientswithCVD-ILDtothosewithoutCVDwereperformed
using unpaired t-tests for normally distributed variables or
Fisher’s exact test and KruskalleWallis tests for non-para-
metric variables.24 A p-value 0.05 was considered signifi-
cant. Analyseswereperformedwith Stata Statistical Software
release 9 (StataCorp, 2005, College Station, TX).Results
The study population of 114 patients with ILD was comprised
of 69% women and 69% Caucasians. Mean age at onset of
symptomswas 58.8  13.4 years; mean disease duration was
2.4  3.2 years (Table 1). The vast majority reported having
pulmonary symptoms or abnormal chest imaging as the pre-
senting feature of ILD. Dyspnea (40%) and cough (25%) were
the most common symptoms at presentation. Among
patients presenting with non-pulmonary symptoms, 6 (5%)
were noted to have subjective muscle weakness.
Overall, there were 34 patients who satisfied criteria for
a well-defined CVD. These were equally divided into
established and new diagnoses of a CVD. Thus, 17 (50%)
patients presented with an established CVD, and anTable 1 Clinical characteristics of ILD subjects with and witho
Characteristics CVD-ILD, nZ 34
Established, nZ




Caucasian, not Hispanic, n (%) 9 (53)
African-American, not Hispanic, n (%) 7 (41)
Asian, n (%) 1 (6)
Hispanic, n (%) 0 (0)
Gender
Female, n (%) 15 (88)
Male, n (%) 2 (12)
Disease duration at presentation,
average years (range)
1.51 (0.3e7.9)b
Reported symptom/sign at onset
Dyspnea, n (%) 6 (35)
Cough, n (%) 2 (12)
Pneumonia with or without infiltrate, n (%) 1 (6)
URI/flu symptoms, n (%) 0 (0)
Abnormal chest imaging, n (%)c 2 (12)
Chest pain, n (%) 0 (0)
Weakness, n (%) 5 (29)
Other, n (%) 1 (6)
Unknown, n (%) 1 (6)
a Comparison between new CVD (nZ 17) and non CVD-ILD subjects
b No significant differences were seen between patients with es
presentation, race, gender, disease duration, and symptoms at disea
c These were asymptomatic patients, identified by an incidental fin
than evaluation of ILD.additional 17 patients were diagnosed with a new CVD
diagnosis subsequent to and as a direct result of their
evaluation at the ILD Clinic. The CVD subtype among the
established CVD-ILD cases were as follows: 5 had idiopathic
inflammatory myositis, 5 had RA, 3 had SLE, 2 had overlap
syndrome, 1 had Sjogren’s syndrome, and 1 had SSc. We
performed univariate analyses of clinical characteristics
between the new CVD-ILD group and the non-CVD-ILD
group. Those with a new diagnosis of CVD were significantly
younger than the 80 patients without a CVD; their mean age
at presentation was 51 compared to 60 years, respectively
(pZ 0.01). There were no other significant differences in
demographic or clinical features between the new CVD-ILD
and the non-CVD-ILD groups.
During the clinical evaluation, 105 patients (92%) had
two or more autoantibodies tested. Seventy-five (66%) of
these patients were seropositive for at least one autoanti-
body whereas 26 patients (23%) had 2 or more positive
autoantibodies. The most frequent positive autoantibody
was an ANA (nZ 61; 56% of patients tested) followed by
rheumatoid factor (nZ 28; 31% of patients tested), then
anti-Ro (nZ 10; 15% of patients tested), anti-Jo-1 (nZ 6;
11% of patients tested), anti-Scl 70 (nZ 3; 5% of patients
tested), and anti-La (nZ 2; 3% of patients tested). Six
patients were evaluated for myositis-associated and
myositis-specific antibodies (other than Jo-1); 2 of these
patients had an anti-PL-7 antibody (nZ 2; 33% of patients
tested) and inflammatory myositis (Table 2). There wasut CVD.
Non CVD-ILD, nZ 80 P-valuea
17b New, nZ 17
51.4 (30e79) 60.0 (26e85) 0.01
1.0
12 (71) 58 (73)
4 (23) 17 (21)
1 (6) 4 (5)
0 (0) 1 (1)
1.0
11 (65) 53 (66)
6 (35) 27 (34)
1.57 (0.3e5.3)b 2.8 (0.1e18.8)b 0.21
0.99
8 (47) 32 (40)
3 (18) 23 (29)
2 (12) 8 (10)
2 (12) 8 (10)
1 (6) 5 (6)
0 (0) 1 (1)
0 (0) 1 (1)
1 (6) 6 (8)
0 (0) 2 (3)
(nZ 80).
tablished CVD and those with a new CVD diagnosis by age at
se onset.
ding on chest imaging, which was performed for purposes other
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results. In particular, of the 29 patients who had a positive
ANA at a titer of 1:320, 18 (62%) had an underlying CVD
(pZ 0.01). In contrast, seropositivity for rheumatoid factor
was not associated with the presence of a CVD diagnosis
(pZ 1.0).
We specifically examined the serologic profile of the
patients with a new CVD diagnosis that followed from their
evaluation at the ILD Clinic. Among these 17 patients, 12
had a positive ANA (71%). Though only 8 were seropositive
for ANA at a titer of >1:320, this titer was only present in 11
of 34 patients without a CVD (pZ 0.049). In addition, 4
(33%) of the patients with a new CVD diagnosis were sero-
positive for anti-Ro; none were seropositive for Scl70 or La
antibody (Table 2). In contrast to the titer level, the
pattern upon immunofluorescence staining did not distin-
guish those with a new CVD from those without CVD-ILD.
The centromere pattern on ANA testing was not present in
any patient.
Diagnostic markers of inflammation were measured in
the majority of the study population (Table 3). Notably, the
erythrocyte sedimentation rate (ESR), an acute phase
reactant and non-specific marker of inflammation, was
elevated in the majority of the patients in whom the test
was performed. However, there was no significant differ-
ence in mean ESR value between patients with and without
CVD. In contrast, markers of muscle inflammation, CPK and
aldolase, were elevated in 26 of 93 (28%) patients with and
22 of 65 (34%) tested patients without a CVD diagnosis,Table 2 Autoantibody profile of ILD subjects with and without
Autoantibody CVD-ILD, nZ 34
Established New
ANA NZ 16 NZ
Positive, n (%) 15 (94) 12
ANA patterna NZ 19 NZ
Speckled, n (%) 9 (47) 5 (4
Homogenous, n (%) 4 (21) 4 (3
Nucleolar, n (%) 6 (32) 2 (1
ANA titer NZ 15 NZ
1:640, n (%) 10 (67) 7 (5
1:320, n (%) 0 (0) 1 (8
1:160, n (%) 3 (20) 1 (8
1:80, n (%) 0 (0) 0 (0
1:40, n (%) 2 (13) 3 (2
Rheumatoid factor (Rf) NZ 16 NZ
Positive, n (%) 8 (50) 3 (2
Anti-Ro NZ 16 NZ
Positive, n (%) 2 (12) 4 (3
Anti-La NZ 16 NZ
Positive, n (%) 2 (12) 0 (0
Anti-Scl 70 NZ 11 NZ
Positive, n (%) 2 (18) 0 (0
NA, not applicable.
a Patients may have more than one pattern.
b Percentages do not add to 100% due to rounding.
c Comparison between new CVD and non CVD-ILD patients.
d Six patients had myositis-associated and myositis-specific (other th
were diagnosed as having a new CVD. Another 53 patients had anti-J
having a CVD (4 with a new CVD).respectively, during their clinical course. There was
a significantly greater proportion of patients with a new
CVD diagnosis who had elevations in CPK and aldolase
compared with the non CVD-ILD group (p < 0.001 and
pZ 0.001, respectively). Thus, even though the median
values for both CPK and aldolase were within the normal
range in all groups, the proportion of patients with values
exceeding the upper limit of normal did, in fact, distinguish
the CVD from the non-CVD group (p < 0.001). There were
no significant differences in median levels of ALT or AST
between the new CVD compared with the non CVD-ILD
group. Interestingly, 12 of the 26 (46%) patients with an
elevated CPK and 10 of 22 (45%) patients with an elevated
aldolase value were ultimately diagnosed with an inflam-
matory myositis.
Seventy-three patients had lung biopsies performed: 61
patients (84%) had surgical lung biopsies while 12 (16%) had
transbronchial biopsies. The most common pathologic
findings on surgical lung biopsy were UIP (nZ 20) in 27% of
patients and NSIP (nZ 18) in 25% (Table 4). NSIP was the
only lung histopathology significantly associated with CVD-
ILD (new and established) (pZ .03). There was a trend
toward significance between histological pattern of NSIP
and a new CVD diagnosis (pZ 0.07). Of the 20 patients with
histological evidence of UIP, 3 (15%) were diagnosed with
a CVD compared with 9 out of 18 (50%) patients with NSIP
(Table 4).
Although only 5 patients reported symptoms of weakness
(Table 1), 21 patients (19%) were found to have objectiveCVD.d
Non CVD-ILD, nZ 80 P-valuec
17 NZ 76
(71) 34 (45) 0.07
11 NZ 32
5) 21 (60) 0.3
6) 3 (9) 0.06
8) 11 (31) 0.5
12b NZ 34
8) 7 (21) 0.03
) 4 (12) 1.0
) 8 (23) 0.4
) 5 (15) 0.3
5) 10 (29) 1.0
12 NZ 61
5) 17 (28) 1.0
12 NZ 37
3) 4 (11) 0.09
12 NZ 37
) 0 (0) NA
11 NZ 42
) 1 (2) 1.0
an Jo-1) antibodies screened and 2 had anti-PL-7 antibodies and
o-1 antibodies evaluated; 6 were positive and were diagnosed as
Table 3 Laboratory evaluation of ILD subjects with and without CVD at presentation to the ILD Clinic.
Laboratory test CVD-ILD, nZ 34 Non CVD-ILD, nZ 80 P-valuea
Established New
CPK elevated NZ 16 NZ 14 NZ 63 <0.001
Elevated, n (%) 8 (50) 9 (64) 9 (14)
Aldolase elevated NZ 11 NZ 14 NZ 40 0.001
Elevated, n (%) 4 (36) 10 (71) 8 (20)
AST NZ 16 NZ 16 NZ 70 0.27
Median (range) U/L 24.0 (12e380) 29.5 (15e218) 21.0 (13e43)
ALT NZ 16 NZ 16 NZ 70 0.08
Median (range) U/L 20 (11e383) 27 (11e161) 22.5 (5e46)
ESR NZ 5 NZ 12 NZ 41
Median (range) mm/h 67.0 (26e85) 29.5 (4e131) 29.0 (1e97) 0.3
ESR elevated NZ 5 NZ 12 NZ 41 0.8
Elevated ESR n (%) 4 (80) 7 (58) 21 (51)
a Comparison between new CVD and non CVD-ILD subjects.
1156 S. Mittoo et al.evidence of muscle weakness on initial examination; prox-
imal weakness was more common than distal weakness.
Histologic evaluation for myositis was quite sensitive, in
that pathologic review was positive for inflammatory
myositis in 6 of 8 patients who underwent a muscle biopsy.
In addition, 22 patients had EMG/NCS performed, among
whom 73% demonstrated either a myopathy or neuropathy.
In this study population of 114 consecutive patients
referred toa tertiary ILDclinic, nearly one-third (nZ 34) had
an underlying CVD. The most frequently associated rheu-
matic disease was inflammatory myositis occurring in 17
patients or one-half of the CVD-ILD group. In addition, 8
patients had SLE (24%), 5 had (15%) RA, and 3 patients had SSc
(9%) (Table 5). While 17 patients presented to the ILD clinic
with a known CVD diagnosis, it is noteworthy that among the
remaining 97 patients, followed for a median of 11 months
(range 0 monthse5.6 years), there were 17 new diagnoses of
CVD. Among the new CVD diagnoses, there were 10 cases of
myositis, 3 of SLE, 2 UCTD, 1 SSc, and 1 case of Wegener’s
granulomatosis (Table 5). The observation that these new
rheumatologic diagnoses were made at a mean interval of
2.2 months (range 0e6 months) following the first ILD clinic
visit, suggests that the phenotypic expression of pulmonary
and non-pulmonary disease manifestations occurred in closeTable 4 Surgical lung biopsy results of ILD subjects with and w
Pathology CVD-ILD
Established, nZ 6b Ne
UIP, n (%) 0 (0) 3
NSIP, n (%) 3 (50) 6




Non-diagnostic, n (%) 1 (17) 0
Other, n (%) 1 (17) 2
UIP, usual interstitial pneumonitis; NSIP, nonspecific pneumonitis; B
diffuse alveolar damage; RB, respiratory bronchiolitis; LIP, lymphocyt
NSIP/UIP.
a Comparison between new CVD and non CVD-ILD subjects.
b Percentages do not add to 100% due to rounding.temporal relationship. Interestingly, two patients were
diagnosed with an overlap syndrome in that they satisfied
published criteria for more than one CVD; there was one
patient with SLE, SSc and myositis overlap and one patient
with SLE and myositis overlap.
Discussion
Interstitial lung disease may evolve from an underlying CVD
and result in substantial morbidity and mortality.1 Whereas
the prevalence of pulmonary fibrosis in patients with
a known CVD has been previously determined by ascer-
tainment for co-existent lung disease among patients pre-
senting first to a rheumatologist,3e6 we sought to determine
the frequency and of new and established CVD diagnoses
among a cohort referred to a pulmonologist for ILD. A
recent editorial underscores the merit of this approach and
highlights the potential for missing the diagnosis of CVD in
patients presenting with ILD as the ‘‘forme fruste’’ of the
CVD.25 Moreover, the identification of CVD-ILD can have
critical importance in therapeutic decision-making and,
likely, has a meaningful impact upon prognosis as well.
We specifically examined the frequency of CVD in
a retrospective cohort of 114 consecutive patients referredithout CVD.
Non CVD-ILD, nZ 53 P-valuea
w, nZ 14
(21) 17 (32) 0.53
(43) 9 (17) 0.07




OOP, bronchiolitis organizing pneumonia. Other includes: DAD,
ic interstitial pneumonitis; HP, hypersensitivity pneumonitis; non-
Table 5 Underlying rheumatologic diagnoses of CVD-ILD
subjects by ACR criteria.








3 (18) 3 (18)
Idiopathic inflammatory
myositis, n (%)
5 (29) 10 (59)
Sjogren’s syndrome, n (%) 1 (6) 0 (0)
Systemic sclerosis, n (%) 1 (6) 1 (6)
Undifferentiated connective
tissue disease, n (%)
0 (0) 2 (12)
Rheumatoid arthritis, n (%) 5 (29) 0 (0)
Overlap syndrome, n (%) 2 (12) 0 (0)
Wegener’s granulomatosis, n (%) 0 (0) 1 (6)
a Percentages do not add to 100% due to rounding; 1 patient
had lupus/myositis overlap and 1 patient had myositis, lupus,
and scleroderma overlap.
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Notably, 17 (15%) patients in this cohort were diagnosed
with a new CVD which satisfied published criteria, as
a direct consequence of their evaluation at the ILD clinic. In
addition, we found that two-thirds (nZ 75) demonstrate at
least one positive autoantibody. The most common auto-
antibodies were ANA and rheumatoid factor in 54% (nZ 61)
and 25% (nZ 28), respectively. A number of clinical and
demographic parameters were further related to the
establishment of a new CVD diagnosis. This included
younger mean age at presentation, elevated levels of the
muscle enzymes, CPK and aldolase, and high titers of
antinuclear antibody.
The overall frequency of CVD in our population,
including both established and new cases, was 30%: twice
that reported in the New Mexico ILD registry, where 13% of
patients with ILD had CVD.26 This higher prevalence may
reflect the referral pattern at our tertiary care ILD clinic.
The relatively higher representation of lupus and myositis
among the new CVD diagnoses in our cohort may similarly
reflect the composition of our referent population or
practice patterns. Nevertheless, our findings emphasize
that a full range of CVD diagnoses may be observed in
patients referred to an ILD clinic. Our experience suggests
that myositis may be under-recognized in the ILD pop-
ulation, as the levels of CK and aldolase are often not
markedly elevated and amyopathic forms of myositis with
isolated lung disease does exist. We also find that at least
one quarter of those with myositis and ILD who demon-
strate anti-synthetase antibodies do not express the Jo-1
autoantibody. Thus, lack of widely available clinical testing
for alternative antisynthetase antibodies might result in the
under-recognition of this syndrome.
Consistent with a number of prior studies, we find that
NSIP is the most common lung histopathology associated
with CVD.9 Nevertheless, over half the patients with CVD
demonstrated pulmonary histopathologic findings other
than NSIP, including UIP in 15% of the patients with a CVD.
This reinforces the notion that a biopsy showing UIP does
not rule out the possibility of an associated CVD. A recentand an earlier study indicate that CVD-UIP has improved
survival in comparison with IPF-UIP.27,28
Our findings need be interpreted in light of the retro-
spective study design. First, the decision to obtain
a particular serologic parameter and the manner in which
the history and examination were conducted may have
been influenced by the individual patient’s symptoms and
the physician’s practice pattern. Future study in this area
ought to incorporate a predetermined protocol for ascer-
tainment of exposures and outcomes applied uniformly to
all patients. Second, there were 39 patients among this
consecutive cohort of ILD referrals for whom no autoanti-
bodies were tested. Exclusion of this quarter of the
referent population due to missing data likely over-
estimated the prevalence of positive autoantibodies and
the frequency of new CVD diagnosis in the remaining 114
patients who formed the basis for our analyses. However,
the demographic profile of the omitted patients, including
age and race, revealed no statistical differences from the
study population, suggesting that the treating physician’s
decision to send autoantibodies was not overtly affected by
demographic characteristics. On the other hand, as CVD is
often a process in evolution, we would predict that
a number of individuals who did not meet criteria for CVD at
the point of evaluation might subsequently do so. As one
such example, one of the non-CVD patients was seroposi-
tive for Scl-70, an autoantibody with specificity for sclero-
derma, but did not yet satisfy diagnostic criteria for that
disorder. Moreover, since the diagnostic criteria for a CVD
are used for research purposes, we may have missed CVD
cases diagnosed on clinical grounds.
Theaccurate recognitionofCVDhas significant therapeutic
and prognostic implication We, therefore, sought to deter-
mine what clinical characteristics and serologic assays used
routinely in clinical practice might identify patients with an
underlying and heretofore unrecognized CVD. We found that
while patients with a new CVD diagnosis were younger at
presentation, there were no other demographic features that
significantly associated with the presence of CVD.
One of the striking findings related to CVD status was the
frequency of high titer positive ANA: a high titer ANA was
associated with a new CVD diagnosis. A homogeneous
immunofluorescence ANA pattern was seemingly associated
with established and new CVD diagnoses. In a separate
study of 276 patients with systemic sclerosis, a homoge-
neous ANA pattern was associated with pulmonary
fibrosis.29 In the same report, a centromere ANA pattern
was negatively related to pulmonary fibrosis.29 Consistent
with these observations, in our study we found no patients
with a centromere pattern among the 61 patients with
a positive ANA and ILD. In contrast to a different recent
study,30 we did not find that rheumatoid factor predicted
CVD, which may reflect demographic differences; our
population was more likely to be female and African-
American.
Our findings suggest that patients presenting for an ILD
consultation merit an evaluation for a previously unrecog-
nized CVD, including aminimum screening for ANA, CPK, and
aldolase. These diagnostic studies all demonstrated high
specificity in our study population, indicating that when
positive, there was a high probability of having a CVD.
Notably, 15% of the patients in this retrospective cohortwere
1158 S. Mittoo et al.diagnosed with a new diagnosis of CVD as a direct conse-
quence of their ILD evaluation. Prompt detection and early
treatment of these patientsmay lead to improved outcomes.
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